Tandem Diabetes Care files 8-K for Q3 2023 earnings; no financial figures in filing

TANDEM DIABETES CARE INC

2023-Q3 EPS reported -$2.97 revenue$550,922,000

Company issued a press release reporting results for quarter ended September 30, 2023.
Press release is attached as Exhibit 99.1; specific numbers (revenue, EPS) are not in the 8-K body.
Investors must consult the exhibit for actual financial performance details.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.